Read the article: https://ow.ly/zuXm50SkgRw Accelerated approvals, staying abreast of rapid changes in data and navigating regulatory intricacies further complicate the commercialization of #oncology therapies. Consequently, challenges like infrastructure, risk spending, and communicating value arise. Learn about considerations and innovative approaches to enhance your commercialization strategies.
EVERSANA’s Post
More Relevant Posts
-
🔍 Join this webinar with VivoSense, Inc. to hear from a diverse panel of experts, representing various viewpoints including regulatory, pharma/industry, clinical, and digital health. Together, they will delve into the comprehensive assessment of physical function in cancer and explore the potential value that digital health technologies can bring to the forefront. 🔗 Learn more and register here: https://buff.ly/3R0c1q2 #Oncology #PatientReportedOutcomes #ClinicalData
-
-
We might be market access experts by trade, but we’re also mythbusters. The biopharma world is full of misinformation and misunderstandings, and our 20+ years of experience lets us cut through the noise and point our clients in the right direction. We’re kicking off a fun, new series today to shed light on some of the most confusing points for #biopharma manufacturers. Today our resident #mythbusters, Michael Thom and Denise Pierce are tackling whether newly-approved treatments are immediately up for hospital review. Is this fact or fiction? You’ll have to watch to find out! #marketaccess #patientaccess #hospitalreview #inpatient #fda #fdaapproval #fdaapproved #oncology #raredisease #cgt #celltherapy #genetherapy #cellandgenetherapy
-
#ASCO2024 starts today and we’re looking forward to putting our new learnings into practice. A common theme we continue to see in the industry is that biopharma companies struggle with effectively reaching the oncologists with the greatest impact on patient care in the community setting. That's where we come in! In a recent 81qd study within oncology, our purpose-built healthcare data analytics software Plexus found that 70% of Clinical Leaders identified were community-based oncologists. Clinical Leaders are the most connected clinicians based on real-world patterns of patient flow. ASCO is the perfect opportunity to put our insights into action and connect with the community. If you’re attending this year’s event, we hope to see you there! #81qd #ASCO #biopharma #oncology #dataanalytics #artificialintelligence
-
-
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/dKcznTas #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
-
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/gdtUNXGe #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
-
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/gCayZcTK #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
-
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/ggMS2SHx #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
-
📅 Meet us at #JPM24 ODC’s CEO and Founder Daniel Zequeto SME is attending the JPMorgan Chase & Co. HealthCare Conference. To schedule a meeting about #LATAM opportunity for #RareDiseases, #Oncology, and #ClinicalTrials, please contact us at contact@orphandc.com Follow our page to stay up to date about LATAM opportunities for your Clinical Trial! #ClinicalTrials #LATAM
-
-
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/eUj38iuZ #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
-
Medical Imaging | Medical Affairs | Clinical Research Professional | Medical Writer
Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/gEhsAmRM #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox
